Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-25T16:28:12.420Z Has data issue: false hasContentIssue false
  • English
  • Français

Urinary detection of olanzapine

Published online by Cambridge University Press:  02 January 2018

Andrew Sander
Andrew Sander*
Affiliation:
Department of Psychiatry and Behavioural Sciences, Royal Free and University College Medical School, Gower Street Campus, Wolfson Building, 45 Riding House Street, London W1N 8AA
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
The Columns
Information
Psychiatric Bulletin , Volume 25 , Issue 1 , January 2001 , pp. 33
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 2000, The Royal College of Psychiatrists

Sir: Coates (Psychiatric Bulletin, August 2000, 24, 316) recently reported the value of urine testing to provide objective evidence of non-adherence with olanzapine by a patient appearing before a mental health review tribunal. While this test has its value in the entirely non-adherent patient, the method may have its limitations with the more canny patient wishing to mislead the tribunal. The half-life of olanzapine is 32.4 hours (Reference CoatesCoates, 1999), which results in olanzapine being detectable in urine for about 6 days after ingestion. In the absence of quantitative testing patients can take olanzapine on an infrequent basis and still appear adherent. A serious concern is that patients might choose to mislead tribunals about their adherence by providing the evidence of positive tests for the presence of olanzapine in their urine by taking olanzapine on an infrequent non-therapeutic basis, in order to help effect their discharge.

References

Coates, J. W. (1999) Urinary detection of olanzapine – an aid to compliance. British Journal of Psychiatry, 175, 591–592.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.